Demyelination (K⁺ channels)

Ongoing clinical trials and approved products targeting Demyelination (K⁺ channels), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials
2ongoing imaging trials
0approved products

Target note

Full name
Unmasked potassium channels
Nature
Labeled 4-aminopyridine binds to the potassium channels exposed when myelin is destroyed.
Normal expression
—
Value
Visualising demyelination.
Approaches
[18F]3F4AP.
Indications explored
Multiple sclerosis, trauma (research).
Points of caution
Early stage.

Ongoing imaging trials · 2Open in the radar →

TrialPhaseStatusSponsorCountries
[18F]3F4AP (potassium channels, demyelination)NCT06999434 · Alzheimer's disease and cognitive disordersPhase 1RecruitingYale University1
[18F]3F4AP (potassium channels, demyelination)NCT04699747 · Neuroinflammation and multiple sclerosisPhase 1RecruitingMassachusetts General Hospital1

Cite this page

Demyelination (K⁺ channels). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/demyelination-k-channels/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.